Hybridan Small Cap Feast: 20/03/2025

* A corporate client of Hybridan LLP

** Potential means Intention to Float (ITF) has been announced, or it is a rumour

***Arranged by type of listing and date of announcement

****Alphabetically arranged

Share prices and market capitalisations taken from the current price on the day of publication

Dish of the day

Admissions:  
One Health Group (AQSE: OHGR), a provider of NHS-funded medical procedures, moved from the AQSE Growth Market to AIM today.  

Delistings:  

None

What’s baking in the oven?

Upcoming Market Movers:

6 February: Creightons (CRL.L) has announced an intention to move to AIM from the Main Market. It is expected that the last day of dealings in the Ordinary Shares on the Main Market will be 28 March 2025. Dealing in the Ordinary Shares is expected to commence on AIM, at 8.00 a.m. on 31 March.

Potential**  Initial Public Offerings:

17th March: MHA, a professional services provider of audit and assurance, tax, accountancy, and advisory services and independent UK member of Baker Tilly International, announced its Intention to Float on the AIM Market.  The Group is seeking to raise up to £125m to provide growth capital for the Company as well as enabling a sell down by certain partners.  Alongside the Placing, the Group intends to launch a retail offer to raise up to approximately £6m.

17th March: Quantum Base, the quantum science Company, announced its intention to apply for Admission to trading on the AIM Market during April 2025.  Quantum Base is a quantum science company creating a new global standard in authentication through its patented Quantum Identities - near unbreakable and non-replicable authenticity tags that can be applied to a vast array of products, significantly mitigating counterfeiting, and can be authenticated with a smartphone.  The Company is seeking to raise between £3m - £5m through a placing, alongside a retail offer.

18th March: Wellnex Life Limited (ASX: WNX) has announced its intention to dual list on to the AIM Market.  Wellnex Life is an Australian incorporated company based in Melbourne, Victoria, Australia, and is in the business of developing, licensing, marketing and distributing consumer healthcare and pharmaceutical products, available in leading retailers and wholesalers across Australia, including Coles, Woolworths, Chemist Warehouse, Sigma and Symbion. One of the Company's brands ('Mr Bright') is also available in the UK through retailers Superdrug and TK Maxx.  £5.22m (A$10.68m) is expected to be raised on Admission, with an anticipated market capitalisation of £21.0m (A$43.1m).   Admission date is set for 21st March 2025.

18th March: Uranium Energy Exploration, to be renamed The Smarter Web Company(AQSE:SWC) is a UK-based web design agency, specialising in creating bespoke, mobile-friendly websites and offers a range of online marketing strategies to help businesses enhance their online presence. Services include various web design packages, logo design, Search Engine Optimisation, animation and custom development. It is looking to do a fundraise of £2m on AQSE. Admission expected 2 April 2025.

18th March: Supersearch Plus (ASQE:SUP) The holding company of a Hong Kong-based frozen seafood importer and wholesaler which specialises in offering a diverse and wide range of frozen seafood products with more than fifty product varieties. Admission expected 25 March 2025.

Banquet Buffet****


The South East Asian energy Company with a natural gas and clean energy portfolio has announced that it has signed a further addendum to the existing Power Purchase Agreement (PPA) with Mobile World Group to deliver power at the next 46 MWG solar sites in Vietnam with an aggregate capacity of c.0.8MW. Construction of the sites subject to the PPA Addendum will commence immediately. As previously announced, the Company signed a Memorandum of Understanding in Vietnam with MWG granting Coro exclusivity on an initial 900 MWG company sites in the central and southern regions of Vietnam where solar irradiation is the highest in the country.  Coro will build, own, and operate each rooftop solar system and sell all generated electricity directly to each Mobile World Investment Corporation location under a 14-year PPA, extendable in certain circumstances.


The AI focused Company today announced the beta launch of Samson, an autonomous AI research agent that performs the work of multiple specialised business analysts at a fraction of the cost. In an industry that has traditionally been reserved for big businesses, Samson makes professional-grade analysis accessible to businesses of all sizes. Following the successful deployment of Lucy, a recruitment digital worker, Cykel's expansion into the market research and business intelligence industry represents a significant opportunity for companies to transform how they access critical insights, and instant scale, allowing them to compete with larger organisations.


The medical device Company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announced the commercial launch and first customer of its SpydrBlade Flex1 technology, a unique multi-modal endoscopic device designed for precision and adaptability in endoscopic procedures, in the UK and Europe. Following extensive pre-launch global clinical activity, this first customer marks the UK & EU commercial launch of SpydrBlade Flex, and is being pioneered in St Mark's Hospital in NW London. Creo will be ramping up the full commercial launch via its core sales channels in the UK and the EU as well as other international territories, including the US, once local regulatory approvals have been received.


The technology business providing Generative Artificial Intelligence services to help research organisations and corporations commercialise their innovations, today announced it has secured a significant contract worth $0.35m with a new client, a research organisation in Saudi Arabia. The contract commences immediately and covers the delivery of 400 GenAI-enhanced analytical assessments and additional technology commercialisation consulting services. Analytical assessment revenue will be recognised upon report production by GenIP and delivery to the Client.


The gold and copper exploration and development Company focused on the Arabian-Nubian Shield has announced that its Gold and Minerals SLA joint venture in Saudi Arabia has been announced by the Saudi Arabian Government as the winner of the tender for the 910km2 Al Hajar North Exploration Licence via a new 50:50 joint venture between GMCO/ARTAR and Hancock Prospecting Pty Ltd, an Australian-based mining group. The Al Hajar North JV was selected from 18 multi-billion-dollar groups that participated in the tenders for five mineralised belts covering 4,788km2 identified as being amongst the most prospective areas for "Global Tier 1" orebodies within Saudi Arabia.


Further to MED's previous RNS announcement dated 19 December 2024, it has signed a binding definitive investment agreement with Powertree Holdings Ltd. The Investment Agreement formalises the long-term partnership between MED and Powertree to deploy capital into the portfolio of development flexible power generation projects that MED owns, starting with its 7.5MW construction-ready Hindlip project. Under the Investment Agreement, Powertree will invest up to £5m into MED's Hindlip project, resulting in the Hindlip project being fully funded, to get the site into commercial production. The Investment Consideration will consist of £500k for 75% of the fully diluted ordinary equity of the Hindlip SPV, ADV 001 Ltd and, up to £4.5m will be by way of secured loan entered into between Powertree and the Hindlip SPV.


The AIM quoted investing Company focused on European gas and power projects recently announced that it has signed a binding agreement to become the sole shareholder of Tarba Energía S.L. by purchasing the entire shareholding that Warrego Energy Ltd holds in Tarba. Tarba is the company through which Prospex holds its investment in the El Romeral production concessions and associated El Romeral gas-to-power plant situated near Carmona in southern Spain and in the Tesorillo and Ruedalabola exploration permits (currently suspended) in the Cadiz province in southern Spain. 


The DRC-focused tin and base metals explorer has today announced that it has entered into a settlement agreement with IM Minerals Limited and the Mozambique government in relation to the Company's legacy claim over the expropriation of a heavy mineral sand mining concession titled 4,623C in 2011. Rome was formerly named Pathfinder Minerals plc until 24 July 2024. As part of the Settlement, the Mozambique government has agreed to grant five new research and exploration licences to a registered Mozambican company (or companies) to be nominated by IM Minerals. In this regard, Rome will receive a 30 per cent. carried interest in the future value of the New Licences.


The buy and build group focused on companies which design and manufacture specialist lab equipment, industrial & scientific sensors and industrial & scientific products, provides an update on portfolio activities. Its industrial & Scientific Products  delivered a  new system of static control  for higher ionising power for adhesive labels in screen and digital printing, which saves costs and energy consumption. The gas measurement and control solutions are being used in a crucial role in aerodynamic testing for top Formula 1 racing teams, ahead of rule changes. Its Decontamination  Equipment has won a place in the NHS Supply chain and for the first time, this framework includes the provision of pathology autoclaves, which it can also provide. Customer-focused product development remains central to  its commercial success and R&D momentum is building.


The petroleum Company today announced that it has signed a Collaboration Agreement with The Strategic Fuel Fund Association, an organisation owned by the State of South Africa. Wildcat and SFF have agreed to work together to evaluate the petroleum assets previously held by Petronas and explore potential scenarios for acquiring all or parts of the assets. This initiative builds on the Memorandum of Understanding (MoU) that Wildcat signed with Nilepet in September 2024. As previously disclosed, Petronas announced the withdrawal of its operations in South Sudan in August 2024, with Nilepet assuming responsibility for all assets and operations previously held by Petronas in South Sudan. Under the MoU with Nilepet, which was valid for six months, Wildcat engaged in productive discussions regarding various options for the acquisition of these assets. Although the MOU expired on 12 March 2025, both parties have agreed to let it lapse while continuing to engaged in productive conversations.


 

This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.

References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results.  Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.

In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.